Research programme: monoclonal antibody therapeutics - Alvos Therapeutics/Juno Therapeutics

Drug Profile

Research programme: monoclonal antibody therapeutics - Alvos Therapeutics/Juno Therapeutics

Alternative Names: Antibody cancer therapeutics - Alvos/Juno Therapeutics; Human antibody therapeutic candidates - Alvos/Juno Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mercator Therapeutics; X-BODY BioSciences
  • Developer Alvos Therapeutics; Juno Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 02 Jun 2015 X-BODY BioSciences has been acquired by Juno Therapeutics
  • 11 Apr 2012 Arrowhead Research Corporation acquires Alvos Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top